SIU Congress 2016: Effect of Gonadotrophin-Releasing Hormone Analogue-Induced Follicle-Stimulating Hormone Suppression on Prostate-Specific Antigen Response - Poster
- Follicle-stimulating hormone (FSH) has been indicated in the development and progression of prostate cancer.
- Coupled with testosterone suppression to castration levels, FSH suppression may delay disease progression, and improve prognosis.
- Degarelix, a gonadotropin-releasing hormone (GnRH) antagonist, has been associated with rapid and profound testosterone and FSH suppression along with prostate specific antigen (PSA) suppression.
- Here we present the factors predicting the FSH suppression including ′on treatment′ PSA suppression from an already published study.
SIU Congress 2016: Bladder cancer: Frailty as a predictor of complications in older patients undergoing radical cystectomy - Session Highlights
Buenos Aires, Argentina (UroToday.com) Sia Daneshmand, Professor at the University of Southern California, discussed use of frailty as a predictor of complications among elderly patients undergoing radical cystectomy.
SIU Congress 2016: Reclassification in patients candidates for focal therapy: correlation between transrectal biopsy and histology of the lesions observed in mpMRI on radical prostatectomy specimens. - Session Highlights
Buenos Aires, Argentina (UroToday.com) Dr. Linares-Quevedo from Infanta Sofia University Hospital discussed the correlation between standard biopsy and histology of lesions as detected on mpMRI as well as that on final pathology at radical prostatectomy (RP).
SIU Congress 2016: Prostate cancer: Prospective study on the correlation between MRI and pathology of radical prostatectomy specimens - Session Highlights
Buenos Aires, Argentina (UroToday.com) Dr. Castellucci and colleagues from Infanta Sofia University Hospital presented a retrospective review of patients with elevated PSA and/or abnormal DRE who underwent multiparametric magnetic resonance imaging (mpMRI) of the prostate.
SIU Congress 2016: Bladder cancer: Radical cystectomy in the elderly- is this a safe treatment option? - Session Highlights
Buenos Aires, Argentina (UroToday.com) Matthew Young from Pinderfields General Hospital, UK assessed RC among elderly patients. Eighty one patients were assessed from 2013-2015 and divided into those < or > 75 years of age.
SIU Congress 2016: Bladder cancer: Underutilization of radical cystectomy among elderly patients diagnosed with clinical stage T2 muscle-invasive bladder cancer - Session Highlights
Buenos Aires, Argentina (UroToday.com) Dr. Ghaffary from The University of Texas Medical Branch in Galveston, Texas, presented a large population-based review of radical cystectomy utilization in the United States. This work has been done previously with data from SEER-Medicare using 1992-2002 data with 21% use of RC among these patients.
SIU Congress 2016: Challenging cases in bladder cancer: High grade T1 bladder cancer: BCG immunotherapy and urine biomarkers of response - Session Highlights
Buenos Aires, Argentina (UroToday.com) Badrinath Konety, Professor University of Minnesota, discussed the diagnosis and treatment of high grade bladder cancer. Regarding diagnosis there are numerous biomarkers and adjuncts to traditional cystoscopy to aid in diagnosis.